Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Kamada Ltd tiene un dividendo anual de 0.00 por acción, con un rendimiento del 0.00%. El dividendo se paga anualmente y la última fecha ex-dividendo fue Mar 17, 2025.